Skip to content

VCM eradication therapy for penicillin allergy

Efficacy of triple therapy with vonoprazan, clarithromycin, and metronidazole as Helicobacter pylori eradication therapy for paritents allergic to panicillin: single arm interventional study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031200171
Enrollment
30
Registered
2020-10-26
Start date
2020-12-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection Helicobacter pylori

Interventions

Sponsors

Sue Soichiro
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients infected with Helicobacter pylori. Patients allergic to penicillin. Patients who give a written informed consent.

Exclusion criteria

Exclusion criteria: Past history of Helicobacter pylori eradication therapy. Pregnancy or lactation. Past history of allergy for the drugs used in this therapy (vonoprazan, clarithromycin, or metronidazole). Patients using atazanavir, rilpivirine, pimozide, ergotamine, suvorexant, lomitapide mesylate, tadalafil, ticagrelor, ibrutinib, asuna previr, ivavradine, venetoclax, lurasidone hydrochloride, anamorelin hydrochloride, finerenone, or isavuconazonium sulfate. Patients using colchicine with liver dysfunction or renal dysfunction. Patients with cerebrospinal disease. Severe liver dysfunction, severe renal dysfunction, severe heart dysfunction. Patients who are disqualified for the study by physicians.

Design outcomes

Primary

MeasureTime frame
Eradication rate

Secondary

MeasureTime frame
Safety

Contacts

Public ContactSoichiro Sue

Yokohama City University Hospital

mkka-kon152016@outlook.jp+81-45-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026